MDT

97.73

+2.28%↑

VEEV

296

-1.38%↓

A

141.89

+2.46%↑

HQY

88.52

-1.34%↓

PHR.US

23.12

+1.54%↑

MDT

97.73

+2.28%↑

VEEV

296

-1.38%↓

A

141.89

+2.46%↑

HQY

88.52

-1.34%↓

PHR.US

23.12

+1.54%↑

MDT

97.73

+2.28%↑

VEEV

296

-1.38%↓

A

141.89

+2.46%↑

HQY

88.52

-1.34%↓

PHR.US

23.12

+1.54%↑

MDT

97.73

+2.28%↑

VEEV

296

-1.38%↓

A

141.89

+2.46%↑

HQY

88.52

-1.34%↓

PHR.US

23.12

+1.54%↑

MDT

97.73

+2.28%↑

VEEV

296

-1.38%↓

A

141.89

+2.46%↑

HQY

88.52

-1.34%↓

PHR.US

23.12

+1.54%↑

Search

REGENXBIO Inc

Open

SectorGezondheidszorg

10.46 -0.85

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

10.43

Max

10.97

Belangrijke statistieken

By Trading Economics

Inkomsten

-77M

-71M

Verkoop

-68M

21M

Winstmarge

-331.809

Werknemers

353

EBITDA

-68M

-56M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+142.63% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

78M

498M

Vorige openingsprijs

11.31

Vorige sluitingsprijs

10.46

Nieuwssentiment

By Acuity

86%

14%

354 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

REGENXBIO Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

22 apr 2025, 09:30 UTC

Top Nieuws

Trump's FDA Sends a Bullish Signal to Biotech -- Heard on the Street -- WSJ

Peer Vergelijking

Prijswijziging

REGENXBIO Inc Prognose

Koersdoel

By TipRanks

142.63% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 25.67 USD  142.63%

Hoogste 40 USD

Laagste 14 USD

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor REGENXBIO Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

9 ratings

8

Buy

1

Hold

0

Sell

Technische score

By Trading Central

6.99 / 7.92Steun & Weerstand

Korte Termijn

Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Bullish Evidence

Sentiment

By Acuity

354 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over REGENXBIO Inc

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
help-icon Live chat